Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 4/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30779755 | 0.79 | CYP2C19 (0.36) | HSD11B1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL4649268 | 0.78 | CA12 (0.42) | HSD11B1ALDH1A1TSHRHPGD | |
| SCHEMBL28820007 | 0.78 | CA12 (0.42) | HSD11B1ALDH1A1TSHRHPGD | |
| SCHEMBL1769221 | 0.78 | CYP2C19 (0.39) | HSD11B1ALDH1A1TSHRHPGD | |
| SCHEMBL16632557 | 0.78 | HSD11B1 (0.34) | HSD11B1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL22871592 | 0.77 | CHRNB2 (0.54) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL21173898 | 0.77 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL21173899 | 0.77 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL5184241 | 0.75 | MAPT (0.38) | ALDH1A1TSHRHPGD | |
| SCHEMBL21828484 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057951-B1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-20 | — | — | EP | disclosed |
| US-9284308-B2 | Methylene linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV | 2016-03-15 | — | — | US | disclosed |
| US-20150105366-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105366-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | HSD11B1 801/4885CHRNB2 1902/4885CHRNA3 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.